Compare BAK & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAK | SLDB |
|---|---|---|
| Founded | 1972 | 2013 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 713.3M | 781.7M |
| IPO Year | 2002 | 2017 |
| Metric | BAK | SLDB |
|---|---|---|
| Price | $1.82 | $6.86 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $1.90 | ★ $18.62 |
| AVG Volume (30 Days) | ★ 1.7M | 1.2M |
| Earning Date | 11-12-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,094,000.00 |
| Revenue This Year | $7.44 | N/A |
| Revenue Next Year | $4.41 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.40 | $3.79 |
| 52 Week High | $5.40 | $11.45 |
| Indicator | BAK | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 53.50 | 29.65 |
| Support Level | $1.40 | $6.76 |
| Resistance Level | $2.16 | $7.26 |
| Average True Range (ATR) | 0.11 | 0.39 |
| MACD | 0.04 | -0.06 |
| Stochastic Oscillator | 82.47 | 9.05 |
Braskem SA is engaged in the manufacture, sale, import and export of chemicals, petrochemicals and fuels, as well as the production, supply and sale of utilities such as steam, water, compressed air and industrial gases. It also provides industrial services and is engaged in the production, supply and sale of electric energy and gas for its own use and use by other companies. Its segments include Brazil, USA and Europe; and Mexico. The Brazil segments delivered the majority of the revenue from the production and sale of chemicals; the supply of electricity and other inputs produced in these complexes to second-generation producers located in the petrochemical complexes; and the production and sale of PE, including the production of green PE made from renewable resources, and of PP.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.